Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sailaja Puttagunta

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
The Western Journal of Emergency Medicine|July 30, 2020
Necrotizing Fasciitis Within 72 hours After Presentation with Skin and Skin Structure InfectionUrania Rappo, H Bryant Nguyen, Sailaja Puttagunta, et al.
NEJM Evidence|June 24, 2025
Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract InfectionSailaja Puttagunta, Steven I Aronin, Jayanti Gupta, et al.
Drugs in Context|December 22, 2018
Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugsPedro Luis Gonzalez, Urania Rappo, Karthik Akinapelli, et al.
Infectious Diseases and Therapy|December 14, 2021
Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical TrialsPedro L Gonzalez, Urania Rappo, Karthik Akinapelli, et al.
The New England Journal of Medicine|June 5, 2014
Once-weekly dalbavancin versus daily conventional therapy for skin infectionHelen W Boucher, Mark Wilcox, George H Talbot, et al.
The Pediatric Infectious Disease Journal|January 1, 2015
Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of AgeJohn S Bradley, Sailaja Puttagunta, Christopher M Rubino, et al.
Plos One|November 16, 2012
The ability of virulence factor expression by Pseudomonas aeruginosa to predict clinical disease in hospitalized patientsMichel Ledizet, Thomas S Murray, Sailaja Puttagunta, et al.
The Journal of Antimicrobial Chemotherapy|April 12, 2023
In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance ProgramJoshua M Maher, Michael D Huband, Christopher G Blankers, et al.
Antimicrobial Agents and Chemotherapy|September 11, 2019
Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram InfusionUrania Rappo, Michael W Dunne, Sailaja Puttagunta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 7, 2022
Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized TrialMichael W Dunne, Steven I Aronin, Anita F Das, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
The Western Journal of Emergency Medicine|July 30, 2020
Necrotizing Fasciitis Within 72 hours After Presentation with Skin and Skin Structure InfectionUrania Rappo, H Bryant Nguyen, Sailaja Puttagunta, et al.
NEJM Evidence|June 24, 2025
Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract InfectionSailaja Puttagunta, Steven I Aronin, Jayanti Gupta, et al.
Drugs in Context|December 22, 2018
Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugsPedro Luis Gonzalez, Urania Rappo, Karthik Akinapelli, et al.
Infectious Diseases and Therapy|December 14, 2021
Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical TrialsPedro L Gonzalez, Urania Rappo, Karthik Akinapelli, et al.
The New England Journal of Medicine|June 5, 2014
Once-weekly dalbavancin versus daily conventional therapy for skin infectionHelen W Boucher, Mark Wilcox, George H Talbot, et al.
The Pediatric Infectious Disease Journal|January 1, 2015
Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of AgeJohn S Bradley, Sailaja Puttagunta, Christopher M Rubino, et al.
Plos One|November 16, 2012
The ability of virulence factor expression by Pseudomonas aeruginosa to predict clinical disease in hospitalized patientsMichel Ledizet, Thomas S Murray, Sailaja Puttagunta, et al.
The Journal of Antimicrobial Chemotherapy|April 12, 2023
In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance ProgramJoshua M Maher, Michael D Huband, Christopher G Blankers, et al.
Antimicrobial Agents and Chemotherapy|September 11, 2019
Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram InfusionUrania Rappo, Michael W Dunne, Sailaja Puttagunta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 7, 2022
Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized TrialMichael W Dunne, Steven I Aronin, Anita F Das, et al.
Pageof 4